4579
RaQualia Pharma Inc.
ラクオリア創薬
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(thousand JPY)
Dec 2021
2,776,233
Dec 2022
2,918,038
Dec 2023
1,901,202
Dec 2024
3,107,575
Dec 2025
3,979,956
Operating profit(thousand JPY)
Dec 2021
707,860
Dec 2022
866,235
Dec 2023
-337,366
Dec 2024
-213,383
Dec 2025
483,719
Operating profit margin(%)
Dec 2021
25.5
Dec 2022
29.69
Dec 2023
-17.74
Dec 2024
-6.87
Dec 2025
12.15
Profit before tax(thousand JPY)
Dec 2021
880,579
Dec 2022
851,011
Dec 2023
-294,049
Dec 2024
-357,732
Dec 2025
437,949
Profit(thousand JPY)
Dec 2021
755,788
Dec 2022
723,390
Dec 2023
-323,662
Dec 2024
-495,031
Dec 2025
273,115
Total assets(thousand JPY)
Dec 2021
5,234,197
Dec 2022
6,257,653
Dec 2023
6,871,972
Dec 2024
9,655,482
Dec 2025
10,514,193
Cash and cash equivalents(thousand JPY)
Dec 2021
2,240,661
Dec 2022
3,679,304
Dec 2023
3,664,738
Dec 2024
3,141,929
Dec 2025
3,244,274
Cash flows from operating activities(thousand JPY)
Dec 2021
366,027
Dec 2022
1,480,084
Dec 2023
-718,596
Dec 2024
180,945
Dec 2025
-354,426
Cash flows from investing activities(thousand JPY)
Dec 2021
-279,251
Dec 2022
-47,649
Dec 2023
-135,373
Dec 2024
-3,665,610
Dec 2025
124,321
Cash flows from financing activities(thousand JPY)
Dec 2021
-16,441
Dec 2022
-29,563
Dec 2023
793,450
Dec 2024
2,982,105
Dec 2025
378,064
Return on equity(%)
Dec 2021
17.2
Dec 2022
14.1
Dec 2023
-
Dec 2024
-
Dec 2025
4.4
Equity ratio(%)
Dec 2021
91.3
Dec 2022
87.7
Dec 2023
88.7
Dec 2024
57.4
Dec 2025
65.1
Earnings per share(JPY per share)
Dec 2021
36.07
Dec 2022
34.5
Dec 2023
-14.98
Dec 2024
-22.87
Dec 2025
11.53
Net assets per share(JPY per share)
Dec 2021
227.97
Dec 2022
261.65
Dec 2023
281.87
Dec 2024
253.83
Dec 2025
280
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.